MMP-9 Binding Proteins Targeting Enzymatic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as cancer, inflammation, heart failure, septic shock, neuropathic pain, and macular degeneration are limited by the inability to effectively target and inhibit excess or inappropriate activity of Matrix Metalloproteinase-9 (MMP-9), which contributes to these conditions.
Innovation Solution
Development of MMP-9 binding proteins, including antibodies and antibody fragments, that specifically bind to and inhibit MMP-9, allowing for targeted therapy by conjugating these proteins with drugs or using them to guide nanoparticles to MMP-9-expressing cells, thereby modulating MMP-9 activity and reducing its harmful effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases such as cancer, inflammation, and heart failure, then general therapy is provided, but the inability to specifically target and inhibit MMP-9 activity limits treatment effectiveness
Solution Approach 1:
The patent employs MMP-9 binding proteins (antibodies and antibody fragments) as intermediary molecules that specifically recognize and bind to MMP-9. These binding proteins act as mediators between the therapeutic agent and the target enzyme, enabling selective inhibition of MMP-9 activity while sparing other matrix metalloproteinases. The binding proteins contain variable regions that specifically interact with epitopes on MMP-9, providing the necessary adaptability for targeted therapy.
2Measurement precision
If MMP-9 binding proteins are used to specifically inhibit MMP-9, then treatment precision is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts and utilizes only the essential antigen-binding portions of antibodies (such as Fab fragments, Fv fragments, and single-chain variable fragments) to create MMP-9 binding proteins. By taking out just the variable regions that provide specificity for MMP-9 binding, the therapy achieves high targeting precision while reducing the complexity associated with using full-length antibodies. This extraction approach maintains the key functional element (specific binding) while simplifying the overall therapeutic construct.
3Adaptability or versatility
If broad-spectrum MMP inhibitors are used, then multiple MMP activities are inhibited, but specificity for MMP-9 is lost and off-target effects increase
Solution Approach 1:
The patent applies local quality by designing binding proteins with variable regions that are specifically tailored to recognize and bind to unique epitopes on MMP-9. Rather than using broad-spectrum inhibitors that affect all MMPs, the invention creates locally optimized binding sites with high specificity for MMP-9 structural features. This localized specificity ensures that only MMP-9 is inhibited, avoiding off-target effects on other matrix metalloproteinases while maintaining the ability to address MMP-9-driven pathologies.
Data Source
AI summary
Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described.